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history of hypertension that might have been identified during
his care for the noted infections.
The patient’s chief complaints were nausea and vomiting.
He had more long-standing symptoms of generalized weakness,
malaise, and chronic headache. He disclosed a list of current
and/or recent medications that included rifabutin, ethambutol,
clarithromycin, nelfinavir, stavudine, lamivudine, trimethoprim-
sulfamethoxazole, loratadine, and amlodipine. Compliance had
been a concern, and the patient recently had initiated a self-
imposed drug holiday. At presentation, his physical examina-
tion was noteworthy for a blood pressure of 180/120 mm Hg;
heart rate ranging from 84 to 112 beats/min; and temperature,
96.9F. The remainder of the physical examination was non-
contributory.
Laboratory values obtained at presentation included a serum
creatinine of 9.5 mg/dL; BUN, 86 mg/dL; uric acid, 7.6 mg/dL;CASE PRESENTATION
sodium, 135 mEq/L; potassium, 4.7 mEq/L; chloride, 106 mEq/L;
A 45-year-old man with long-standing HIV infection pre- total CO2, 18 mEq/L; total protein, 6.1 g/dL; albumin, 2.3 g/dL;
sented to the emergency room at his local medical center. total bilirubin, 0.6 mg/dL; glucose, 104 mg/dL; and calcium, 8.2
Complications of his HIV infection in the past had consisted mg/dL. Urinalysis revealed 1 blood and 3 protein; micro-
of numerous opportunistic infections including toxoplasmosis, scopic examination of the urine sediment showed 6 to 8 white
pneumocystis pneumonia, cytomegalovirus retinitis, chronic blood cells and 4 to 8 red blood cells/high-power field and no
vertebral osteomyelitis resulting from infection with an atypical casts. More quantitative assessment of the degree of protein-
mycobacterial organism (M. avium intracellulare), and rectal uria was not performed. Urine cultures grew no organisms. A
herpes. He had received multiple combinations of anti-retro- complete blood count revealed a hematocrit of 26.3%; hemo-
viral therapy for his primary infection as well as therapies globin, 8.8 g/dL; and white blood cell count, 3600/mm3, with
directed more specifically to the various infections he had en- 75% neutrophils, 14% lymphocytes, 7% monocytes, 3% eosin-
countered. Other specific details of his HIV infection history ophils, and 1% band forms. The platelet count was 76,000/
such as blood counts, lymphocyte subsets, and measurements mm3. A peripheral blood smear revealed red cell macrocytosis
of viremia were unavailable. Other than complications of his and schistocytes.
HIV infection, the patient’s medical history included a renal Therapy aimed at achieving acute control of the patient’s
stone that underwent successful basket retrieval five years pre- blood pressure was instituted, but the serum creatinine and
viously and extraction of a cataract approximately seven BUN did not improve over the subsequent two days. Because
months prior to the current presentation. He had had renal of issues related to the recently recognized renal insufficiency
insufficiency (serum creatinine of approximately 2.0 mg/dL) and the desire to exclude treatable causes of renal failure and
approximately one year prior to the current presentation, but plan for institution of dialysis, a renal biopsy was performed
he declined further workup at that time. The patient reportedly and referred to the University of Washington for evaluation.
had normal blood pressure at that time and reportedly had no
Renal biopsy microscopic description
Sections of the renal cortex contained greater than 75 glo-
The Nephrology Forum is funded in part by grants from Amgen, meruli, of which all but three or four per level section wereIncorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
completely sclerosed. Several of the intact glomeruli showedrated; and Bristol-Myers Squibb Company
prominence of intracapillary foam cells with foci of mesangio-
Key words: AIDS, mesangiolysis, endothelial injury, hemolytic-uremic lysis characterized by dissolution of the adjacent mesangial
syndrome, thrombotic thrombocytopenic purpura, HIV-associated ne- matrix. These glomeruli showed focal thickening and reduplica-
phropathy. tion of peripheral capillary basement membranes. The glomer-
ular tufts also showed segmental prominence of glomerular 2003 by the International Society of Nephrology
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Fig. 1. Pathologic features of the kidney in
TMA. (A) A partially scarred glomerulus dem-
onstrates features of mesangiolysis (arrow) and
segmental peripheral capillary wall changes
including thickening and splitting of basement
membranes. (B ) Small arterial and arteriolar
vessels containing intraluminal thrombi, some
of which contain red cell fragments and fibri-
nous material [inset].
Table 1. Causes of thrombotic microangiopathyvisceral epithelial cells, which frequently appeared swollen and
contained prominent intracytoplasmic protein reabsorption Hemolytic–uremic syndrome
droplets. Features of overt segmental sclerosis or glomerular Thrombotic thrombocytopenic purpura
capillary collapse were not identified. The tubular parenchyma Malignant hypertension
Eclampsia/pre-eclampsiashowed broad areas of interstitial fibrosis with broad areas of
Post-partum renal failuretubular atrophy, which was focally pronounced. Some tubular
Oral contraceptivessegments exhibited prominent dilation. A prominent intersti-
Infectionstial inflammatory infiltrate was composed predominantly of Allograft rejection
mononuclear cells. Arterial vessels demonstrated intimal scle- Scleroderma
rosis without evidence of vasculitis. Several smaller arterial Systemic lupus erythematosus
Anti-phospholipid antibody syndromeand arteriolar vessels showed features of intraluminal thrombo-
Hereditysis (Fig. 1).
RadiationImmunofluorescence studies revealed nondescript segmen-
Disseminated intravascular coagulationtal staining of some glomeruli for C3 only. Deposits of IgG, Drugs/toxins
IgM, IgA, C1q, kappa and lambda chains, fibrinogen, or albu- HIV infection
min were not identified.
Ultrastructural examination of two glomeruli disclosed promi-
nent expansion of mesangial regions due primarily to accumula-
tions of increased matrix. Peripheral capillary walls showed
thromboses, are present in the renal biopsy, and charac-irregular thickening. Overlying epithelial cells revealed focal
teristic changes of TMA involving glomerular capillaryeffacement of foot processes, but some of these remained pre-
served. Features of overt thrombosis were not identified within walls are not prominent. The presence of severe, nearly
the glomerular capillary loops. Electron-lucent widening of the end-stage renal injury might be unrelated to the acute
subendothelial space was not clearly identified. Glomerular intravascular thromboses that are present. Although TMA
endothelium was focally swollen, but was without prominent
is a nonspecific term, it can encompass a wide variety oftubuloreticular structures.
diseases and initiating events (Table 1) [1]. Nonetheless,
if we make use of the clinical and pathologic details
DISCUSSION available, this case offers us an opportunity to consider
the relationship of HIV infection and thrombotic mi-Dr. Charles E. Alpers (Professor of Pathology, De-
croangiopathy. It allows me a particular opportunity topartment of Pathology, University of Washington Medical
link two long-standing research interests of my laboratory:Center, Seattle, Washington, USA): This case is an exam-
the mechanisms underlying glomerular mesangiolysis andple of thrombotic microangiopathy (TMA) in a patient
its repair, and the development of relevant models ofinfected with HIV. The case is ambiguous, and all of us
HIV-associated renal injury.can recognize that alternate interpretations of the clinical
Thrombotic microangiopathy involving the kidneyfindings are possible. Key clinical and laboratory data
was first described in an AIDS patient by Boccia et althat would enable us to unequivocally establish the diag-
in 1984 [2]. Subsequently TMA has been reported innosis and its pathophysiologic basis are lacking. Only
some features of TMA, mesangiolysis and microvascular several hundred HIV-infected humans worldwide and
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appears to be the most common microvascular injury new or progressive renal insufficiency at other centers,
but these findings do indicate that the number of affectedassociated with HIV infection [3–14]. The review by Bell
et al documents the increasing recognition of HIV-asso- patients is substantial and therefore this condition might
well be under-recognized. From my review of publishedciated TMA encompassing reports published through
mid-1996 [11]. case reports to date, no specific clinical feature of HIV
infection (for example, blood counts, infection with spe-In humans, as in rodent models, TMA injury involves
damage to the endothelial lining of capillaries and arterial cific organisms, therapy with specific antiviral agents)
particularly predisposes to the development of TMA.microvessels, with activation of the plasma coagulation
cascade causing thromboses in these vessels [1, 15]. The
Pathogenesiskidney is perhaps the organ most susceptible to injury
from TMA [15, 16] and typically demonstrates patho- The pathogenesis of TMA revolves around direct en-
dothelial damage. Whether cells are injured directly bylogic findings of occlusive thrombi in small arteries and
arterioles, detachment of glomerular endothelial cells toxins, shear stress, vasoactive factors, or immune/inflam-
matory injury, the endothelial response produces a localfrom the basement membrane, glomerular mesangiolysis,
widening of the subendothelial space of glomerular capil- state in which coagulation (through such mechanisms as
secretion or increased surface expression of procoagulantlaries by electron-lucent material presumed to be derived
from plasma, and reduplication of capillary basement molecules, decreased fibrinolytic activity, platelet activa-
tion, exposure of subendothelial thrombogenic matrices,membranes as a consequence of either new basement
membrane synthesis and/or “splitting” of the capillary release of von Willebrand factor multimers, and leuko-
cyte activation) and intravascular thrombosis are favored.walls by interposed cells and/or insudated plasma and
plasma proteins [15]. Accordingly, patients with HIV- This injury appears to be unrelated to any form of im-
mune-complex deposition in glomeruli or blood vessels.associated TMA often present with hemolytic-uremic
syndrome (HUS), in which clinically evident organ dys- Extrapolating from a similar injury that occurs in some
patients with systemic lupus erythematosus, and on thefunction is limited to the kidneys and blood and which is
manifest as renal insufficiency, hemolytic anemia, platelet basis of surveys of blood samples of asymptomatic HIV-
infected patients [18], some researchers have postulatedconsumption, and fragmentation of red blood cells (schis-
tocyte formation). When the TMA process results in a role for circulating anti-phospholipid autoantibodies
in initiating this injury [19–24]. Uthman and Gharavisevere extrarenal manifestations, the term thrombotic
thrombocytopenic purpura (TTP) has been employed to recently pointed out that anti-phospholipid/anti-cardio-
lipin antibodies are a common finding when sought in thedenote the systemic nature of the microvascular injury
and clotting processes. HIV-infected population but are of unknown significance
because the majority of individuals with such findings (anti-An immediate area of uncertainty concerns the magni-
tude of the problem. Some data suggest that HIV-associ- bodies) lack evidence of clinically relevant thrombotic
events [19]. A particularly relevant study of 85 patientsated TMA is an under-recognized clinical entity. The diag-
nosis of this injury can be difficult if the clinical findings infected with HIV found a 40% prevalence of anti-phos-
pholipid antibodies, the presence of which could not beare largely limited to the kidney and the entity is unsus-
pected. At times, HIV-associated TMA might be recog- correlated with either thrombotic events or other manifes-
tations of AIDS [20]. Studies by one French group indi-nized only by characteristic findings in renal biopsies and
hence might be underdiagnosed because of physicians’ cate that circulating levels of one molecule important
in the regulation of fibrinolysis, plasminogen activatorfrequent reluctance to perform such biopsies in patients
with HIV infection. Two studies that are helpful in defin- inhibitor type 1 (PAI-1), is not altered in HIV-infected
patients with TMA [21]. Based on this finding, Peraldiing the prevalence of this entity include a multicenter
autopsy study in which 15 of 214 patients (7%) whose et al concluded that HIV-associated TMA is unlikely to
result from decreased fibrinolytic activity. Studies of cul-deaths were attributable to AIDS had evidence of TMA
at the time of death [17]; and a study from France by tured human endothelial cells suggest that exposure to
plasma of patients with TMA, including one patient withPeraldi et al, in which the most common etiologic basis
for acute or rapidly progressing renal failure in patients HIV-1 infection, causes endothelial cell injury and apo-
ptosis, which in turn could promote TMA directly or bywith HIV infection was HUS, the diagnosis having been
established by renal biopsy in the great majority of cases exposure of thrombogenic matrix underlying dead and
detached endothelial cells [22, 23]. A 1993 report cited[13]. This diagnosis was more prevalent than the typical
form of HIV-associated nephropathy or allergic- or in- evidence of direct HIV infectivity of endothelium, which
could lead to phenotypic changes promoting coagulation,fection-related acute interstitial nephritis and involved
32 of 92 patients in this large study. It is not clear that but these data have yet to be substantiated [7]. In the
absence of CD4 expression, the major receptor mediatinga similar proportion of patients with TMA would be
found among the HIV-infected patient population with HIV infection of leukocytes, it has been difficult to define
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a mechanism for HIV infectivity of endothelial cells, studies from Paul Klotman and his colleagues, utilizing
sophisticated in situ PCR techniques to detect circularalthough one study in simian models has demonstrated
that endothelial cells of brain capillaries, a recognized forms of viral DNA, has provided evidence that podo-
cytes and entire tubular segments can be infected withsite of TTP/TMA injury, can be infected by immunode-
ficiency viruses utilizing chemokine receptors indepen- HIV in vivo [33–36]. These studies have not identified
viral infection of renal microvascular cells. In view ofdently of CD4 receptors [24].
Because direct renal microvascular infection by HIV the persistent difficulty in identifying HIV peptide prod-
ucts or other evidence of a productive infection in thesehas not been demonstrated, it behooves us to consider
alternate mechanisms that might cause microvascular in- infected epithelial cells, it remains difficult to define the
scenario by which this cellular infection leads to the paren-jury and subsequent TMA. Several promising studies have
been published recently. Studies of human umbilical vein chymal changes of HIV-associated nephropathy (HIVAN)
or other HIV-associated pathologies. Obviously this pre-endothelial cells (HUVEC) in culture demonstrate that
these cells can undergo apoptotic injury when exposed sents a major challenge for individuals engaged in the
investigation of HIV-associated renal disease.to intact HIV virions or subunit peptides [25]. The rele-
vance of this finding for the renal microvasculature is The ability of HIV to directly infect intrinsic renal and
renal microvascular cells also has been investigated inuncertain because HUVECs can express the chemokine
receptors CCR5 and CXCR4, important co-receptors cell culture. We have been unable to demonstrate pro-
ductive infection of human mesangial cells, a cell typewith CD4 in mediating HIV infection of susceptible cells,
unlike renal endothelium. Evidence indicates that the considered to be a variant of vascular smooth muscle
cells, despite exposure of these cells to a variety of wild-Tat (transactivator of viral replication) peptide produced
by HIV-1 can cause apoptosis of cultured human micro- type and laboratory-adapted strains of HIV-1 and HIV-2
[37]. In a recently published letter, Conaldi et al reportedvascular endothelial cells [26], but postulating a role for
Tat as a cause of TMA must be tempered by the experi- successful infection of mesangial cells [38], but many
of the details needed to establish this finding were notence to date with Tat transgenic mice, which can develop
multiple types of tumors, including one resembling Kapo- provided, and we await an expanded description of this
work. One other group has reported HIV infectivity ofsi’s sarcoma, but which do not appear to develop TMA.
Finally, data suggest that the HIV envelope protein human glomerular endothelial cells in vitro and of a
small proportion of mesangial cells but not epithelialgp120 can induce expression of tissue factor, an impor-
tant procoagulant molecule, in cultured human arterial cells [39]. A viral receptor or other mode of entry of
virus into these cells was not identified in this study, andsmooth muscle cells [27]. Such a process, if confirmed
in vivo, could be an important contributory mechanism the study design suggested that the observed findings
were the result of transfection rather than infection ofto the development of HIV-associated TMA in patients.
Despite these intriguing studies, the pathogenesis of the virus. In toto, the results of cell culture studies to
date have not provided clearly defined mechanisms ofHIV-associated TMA remains poorly understood. One
central question remains: does the virus directly infect renal microvascular infection by HIV.
Our understanding of HIV infectivity is further com-intrinsic microvascular or other renal cells in the course
of this disease? Until recently, the evidence that HIV plicated by our limited knowledge concerning possible
receptors for viral entry into specific microvascular renalcould directly infect renal parenchyma was scanty, rest-
ing primarily on an in situ hybridization study demon- cell types. The importance of the leukocyte surface anti-
gen CD4 as a principal receptor mediating entry of HIVstrating viral genomic material in podocytes [28]. We and
others found this evidence difficult to replicate (abstract; into cells has been long established. Chemokine recep-
tors have been identified as essential co-receptors forPardo et al, FASEB J 5:A907, 1991) [29–31]. Additional
evidence for infection of renal cells came from a study human immunodeficiency virus infection in mammalian
cells [40, 41]. The chemokine receptor CCR5 serves asby Kimmel et al, who used polymerase chain reaction
(PCR) amplification techniques to demonstrate HIV vi- the major co-receptor together with CD4 for macrophage-
tropic strains of HIV-1 [42, 43], whereas T-lymphocyte-ral DNA in microdissected glomeruli, tubules, and leu-
kocytes from renal biopsies of HIV-infected patients tropic strains of HIV-1 most often utilize the chemokine
receptor CXCR4 as the principal co-receptor required for[32]. However, identification of this genomic material
did not clearly correspond to manifestations of HIV- infection [40, 44]. The expression of CCR5 and CXCR4
in HIV-associated TMA renal disease is unknown. Ourassociated disease in these patients. Because of the risk of
leukocyte contamination in such difficult microdissection laboratory published data showing that constitutive ex-
pression of these receptors in human and macaque renalprocedures, the exquisite sensitivity of PCR amplifica-
tion, and the lack of an identifiable receptor for HIV on parenchyma and in the renal microvasculature is unde-
tectable using probes for mRNA that code for CCR5 andmost renal parenchymal cells, an element of uncertainty
accompanied these findings. More recently, a series of CXCR4 [45, 46]. In the case of CCR5, this finding has
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Table 2. Animal models of thrombotic microangiopathybeen substantiated by corroborative studies of CCR5
protein expression by immunohistochemical techniques Induction by anti-mesangial cell antibodies
Induction by anti-endothelial antibodies[47]. To date, no evidence supports constitutive expres-
Induction by mesangial toxins (mitomycin, Habu snake venom)sion in vivo of CD4 by intrinsic renal cells. Furthermore, Hypertension (DOCA salt)
we were unable to detect up-regulated expression of these Shiga toxin
HIV infectionreceptors on intrinsic renal cells in renal biopsies from
patients with HIV-associated nephropathy [13]. Absent
the presence of known receptors that can mediate infec-
tion of cells by HIV, it becomes more difficult to con- cell antibodies. The anti-Thy 1 model has been exten-
sively studied by numerous investigators [51]. The majorstruct the early events by which HIV enters renal cells
and/or causes renal injury, unless the pathogenetic basis findings in this model can be summarized: the initial
injury of mesangiolysis is induced by an antibody di-for injuries associated with HIV is indirect and involves
other systemic or locally produced mediators such as cyto- rected against the Thy 1 antigen present on the surface
of mesangial cells and is followed by a reparative re-kines. A recent abstract suggested the possibility that addi-
tional HIV co-receptors (in this case, GPR15/Bob) are sponse that includes mesangial cell proliferation and mi-
gration, which are mediated at least in part by growthpresent in the kidney and might contribute to infection
of renal cells (abstract; Clayton et al, Lab Invest 82:276A, factors FGF-2, PDGF-B, and PDGF receptor ; a capil-
lary regenerative response likely mediated at least in2002). This study also contained evidence that the glyco-
sphingolipid Gb3 (globotriaosyl ceramide), already known part by VEGF [52–54]; formation of a provisional matrix
mediated by TGF-; and restoration of glomerular nor-to be present in the kidney and implicated in the TMA
injury induced by Shiga toxin [48], might have the ability mocellularity through apoptosis, a process in which the
key regulatory factors remain unknown [55].to bind surface proteins (gp120) of some strains of HIV-1.
If these findings are substantiated, characterization of The second rodent model produces a similar lesion of
mesangiolysis, albeit by a different mechanism. In thisnew pathways of viral infectivity could help resolve some
of the uncertainties about the linkage between renal case, mesangiolysis and TMA follow the administration
of anti-endothelial antibodies. This model demonstratesinfection and renal injury.
The pathogenesis of TMA occurring outside the set- a predictable sequence of endothelial injury, intracapil-
lary thrombosis, mesangiolysis, widening of the glomeru-ting of HIV infection is multifactorial. Some causative
agents have been well defined, including products of lar subendothelial space, and complete resolution of the
glomerular injury with morphologic findings remarkablybacterial infection (verotoxins such as Shiga toxin from
Shigella dysenteriae and Shiga-like toxins from E.coli similar to the pathologic findings in human cases of TMA
[56]. This predictable sequence of injury, induced solelyO:157, and bacterial and viral neuraminidases), certain
drugs (for example, mitomycin, cyclosporine, tacrolimus, by an initial insult to the endothelium, is highly relevant
to our current understanding of TMA associated withand oral contraceptive agents), radiation, and circulating
antiphospholipid antibodies [1, 15]. Certain disease set- HIV infection. Together, the two rodent models illustrate
how features of TMA can arise either from an injury totings also predispose patients to this form of injury, in-
cluding malignant hypertension (a relevant consideration the mesangium or to the glomerular capillary endothe-
lium. These models suggest how diverse and perhapsin the patient presented), scleroderma, and eclampsia.
A small minority of affected individuals has a familial, multifactorial pathogenetic events can lead to a common
pattern of renal injury.inherited disorder of von Willebrand factor multimers,
which predisposes them to relapsing episodes of TMA Our interest in the problem of HIV infection-associated
TMA originated in part from our group’s attempt to estab-[1, 15]. In a significant number of individuals with idio-
pathic TMA, the pathogenesis remains undetermined, lish a primate model of renal disease that resembled human
HIVAN. We believed that an animal model that closelyalthough two reports indicate a pathogenesis resulting
from the presence of circulating antibodies that act as inhib- mimicked the lesions seen in human HIV expression
would provide the best opportunity for clarifying manyitors of von Willebrand factor-cleaving protease [49, 50].
questions that have arisen regarding the significance of
Laboratory studies this renal lesion. Our previous studies of primates infected
with simian immunodeficiency virus (SIV), simian retrovi-Researchers have developed a number of animal mod-
els of thrombotic microangiopathy (Table 2). Working rus type D (SRV), HIV-1, or HIV-2 have taught us that
macaques infected with SIV, HIV-2, and possibly HIV-1with colleagues formerly at the University of Washing-
ton, Richard Johnson and Masaomi Nangaku, and their can develop all the manifestations of human HIV infection
including features such as lymphocyte depletion, lymph-fellows and visiting scientists, we have focused on the
anti-Thy 1 antibody rat model of mesangiolysis and re- oproliferative disorders, encephalitis, and opportunistic
infections. Further, these manifestations depend some-pair, and on a model of injury induced by anti-endothelial
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Fig. 2. (A ) Glomerulus from a macaque with HIV-2 infection-associated thrombotic microangiopathy. Note the intracapillary thromboses (arrow).
(B ) Same glomerulus as in A, in a replicate tissue section, showing widespread cellular staining (dark, homogeneous nuclear staining) with the
TUNEL procedure. (C ) Lower-power view of histologic section of kidney from a macaque with TMA, stained by the TUNEL technique. Note
the staining of cells comprising glomeruli and the vasculature in an area involved by the injury process, while other portions of the kidney remain
completely unaffected.
what on the viral strain used for infection and on varia- that exposure to plasma of HIV-1-infected patients with
tions in host species [57–59]. We have learned from these TMA can lead to endothelial cell injury and apoptosis.
models that it is very difficult to demonstrate direct viral An interesting study by Bodi et al identified increased
infection of host epithelial or mesenchymal cells, includ- apoptosis of tubular epithelial cells in renal biopsies of
ing vascular cells; that expression of the viral receptor patients with HIVAN but did not reveal similar apo-
CD4 generally remains limited to cells of hematopoietic ptotic injury within the microvasculature [63]. Studies of
origin; and that a few macaques get renal lesions resem- human proximal tubular epithelial cells in culture also
bling HIVAN [57], but that overall a robust model for have provided evidence of increased susceptibility to
this particular injury has not been established either in apoptosis in the setting of HIV-1 infection [64]. We have
our center or in other primate centers working with vari- evidence, first obtained by electron microscopic exami-
ous simian models of AIDS. However, we now know nation of tissue from macaques with TMA, that this
that macaques infected with the HIV-2287 virus clone disease process involves endothelial and vascular smooth
have an approximate 25% incidence of TMA within a muscle cell injury morphologically resembling, but not
one month period of infection following inoculation with equivalent to, apoptosis (Fig. 3). This injury is character-
the virus [60]. ized by condensation of nuclear chromatin into dense
Although the exact origin of HIV-2 remains unidenti- aggregates in cells of the microvasculature affected by
fied, Hirsch et al suggested that HIV-2 probably origi- TMA and cells enmeshed within thrombi, but not in
nated as a zoonotic disease transmitted from feral sooty other portions of the same tissue, including similar vascu-
mangabey monkeys found throughout western Africa [61]. lar structures that are uninvolved by the TMA process.
One strain of HIV-2 (HIV-2287), originally derived from This last finding, and the absence of such changes in
a human AIDS patient, is not only readily infectious in
numerous uninfected primates and in primates infected
macaques but also highly pathogenic, progressing to a
with SIV, indicates that this form of endothelial injuryclinical AIDS syndrome within an accelerated time frame
is not an artifact or an unrelated finding common toof 6 to 12 months [62]. We demonstrated that approxi-
macaques. This ultrastructural appearance is unique andmately 25% of macaques inoculated intravenously with
differs from the homogeneous clumping of nuclear chro-this strain of HIV-2 and sacrificed in a prospective fash-
matin commonly accepted as pathognomonic of apopto-ion develop pathologic manifestations of TMA (Fig. 2)
sis, although the evidence that links apoptosis to TMA[59]. These animals show a decline in peripheral CD4
raised the possibility that the HIV-2-associated injuryand blood cells but do not develop overt features of
might be similar to apoptosis. Further investigation of thisAIDS or renal insufficiency within the time period stud-
injury process by Frank Eitner and Stephan Segerer in myied. The animals with TMA developed thromboses in
laboratory, who used a variety of morphologic techniquesboth renal and extrarenal sites, and the histologic and
that characterize apoptosis, revealed a unique patternultrastructural pathologic findings (thromboses, mesan-
of tissue injury in which vascular structures involved bygiolysis, detachment of endothelial cells from glomerular
the TMA process, as well as nearby cells comprisingbasement membranes) were remarkably similar to those
other tissue compartments, demonstrate widespread cellof human TMA.
I have cited evidence obtained from in vitro studies labeling by the TUNEL procedure in histologic sections
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There was strong concurrence in the detection of cell
injury utilizing these techniques.
Because of the striking demonstration of discrete areas
of injury marked by TUNEL positivity, we informally
refer to this injury as tunelosis (abstract; Segerer et al,
J Am Soc Nephrol 11:551A, 2000). As detailed in Table 3,
tunelosis differs from apoptosis by a number of features,
notably including the involvement of groups of cells
within tissue compartments and the unique nuclear changes
(Fig. 3). On the other hand, tunelosis also has features
that distinguish it from necrosis, which can involve groups
of cells and tissue compartments but differs in the mor-
phologic appearance of affected cells and does not result
in positive labeling by techniques that identify single
strands and breaks of nuclear DNA [67, 68].
We currently believe that tunelosis is a unique form
of cellular injury, one certainly linked to the pathogenesis
of TMA occurring in HIV-infected macaques. We do not
yet know whether such an injury occurs in human disease
or what features of HIV infection in macaques produce
such a phenotype. These issues are currently being ex-
plored. Renal biopsies from patients with TMA, both
HIV-associated and not, are being investigated by the
same techniques used to characterize injury in the ma-
caques. Cell culture systems using microvascular endo-
thelial cells have been set up to evaluate changes in these
cells that might be induced by HIV virions or peptides
as well as cytokines and other molecules that might be
circulating in the blood of infected patients and non-
human primates. We are hopeful that these studies will
provide clues to the pathogenesis of HIV-associated TMA.
Treatment
Before concluding, I’d like to return to the patient
presented. This patient had limited treatment options
because of the background of end-stage sclerosing renal
injury. Unfortunately, even without such a compromised
Fig. 3. Ultrastructural appearance of macaque glomeruli involved by
background, patients with this disorder have limited op-HIV-2-associated TMA. (A ) Intracapillary thromboses are present (as-
terisks). (B ) Another glomerulus demonstrating characteristic ultra- tions. There are sporadic reports of treatment of affected
structural nuclear changes in capillary endothelial cells, mesangial cells, patients with prednisone and/or plasmapheresis, but the
and visceral epithelial cells. (C ) High-power view of a glomerular mes-
limited number of patients seen in most centers precludesangial cell with characteristic nuclear alterations. Glomerular cells dem-
onstrate a unique, dispersed, speckled pattern of chromatin organization controlled clinical trials to establish the efficacy of such
within the nuclei. treatments. Plasmapheresis has perhaps been the most
widely employed therapeutic modality, but it has had
only limited success [69]. Available reports do not offer(Fig. 3) [65]. The TUNEL procedure stains loose single-
a compelling case for any therapy beyond what mightstranded fragments of DNA and is considered a sensitive,
although not necessarily specific, marker for apoptosis. be employed in TMA arising in other disease states.
The finding of areas of TUNEL-positive cells was con-
fined to macaques with evidence of TMA. This feature
QUESTIONS AND ANSWERSof cell injury corresponded to the cells with altered histo-
Dr. Nicolaos E. Madias (Executive Academic Dean,logic nuclear detail associated with TMA and with other
Tufts University School of Medicine, Boston, Massachu-morphologic markers that are considered somewhat spe-
setts): Collapsing focal glomerulosclerosis occurs in non-cific for apoptotic cell injury, such as in situ end labeling
HIV infected individuals. Also, thrombotic microangiopa-(ISEL) of single-stranded DNA and staining with a mono-
clonal antibody that detects single-stranded DNA [66]. thy has been associated with a number of viral diseases,
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Table 3. Comparison among the pattern of injury in HIV-2-infected macaques and the features of apoptotic and oncotic necrosis
Necrosis Apoptosis Cellular injury in HIV-2-infected macaques
Nuclei Swelling Shrinkage Swelling
Pale Dense Pale
Karyolysis Karyorrhexis
Cells Swelling Segregation into “apoptotic bodies” No distinctive features other than nuclear changes
Disintegration
Chromatin Irregular clumps (coarse strand) Condensation into blebs near the Condensation into a dense center, surrounded by
nuclear envelope diffusely distributed small particles
Distribution Groups of cells Single cells Groups of cells
Inflammation Yes No No
TUNEL Usually negative Positive Positive
ssDNA Usually negative Positive Positive
including cytomegalovirus and parvovirus. Might it be cytokines, all of which can participate in microvascular
injury and lead to thrombotic microangiopathy. The un-that both the renal disease and the microangiopathy in
known variables involved in such a process are many.HIV-infected individuals are actually due to superinfec-
Dr. Madias: How much do we know about factorstion with a different viral agent?
that determine susceptibility of HIV-infected patients toDr. Alpers: The idea that collapsing glomerulopathies
thrombotic microangiopathy? Do these patients havemight be caused by viral infections, perhaps as a result
abnormalities in factor H, von Willebrand factor-cleav-of direct infection of glomerular epithelial cells, has some
ing protease, or polymorphisms in cytokine genes thatappeal on clinical grounds and some supporting evidence
might contribute to decreased thromboresistance?as well. Indirect evidence is based on clinical observa-
Dr. Alpers: This is a critical but currently unanswer-tions that patients with collapsing glomerulopathy often
able question. Few studies to detect these kinds of abnor-
have a prodrome that seems to be a manifestion of some
malities in HIV-infected patients have been done. I did
unspecified flu-like viral illness. Isolation of viral DNA cite some studies from several groups that have looked
from renal biopsy specimens from affected patients and at the issues of circulating anti-phospholipid antibodies
localization of viral DNA by in situ hybridization have and plasminogen activator inhibitor-1 in the setting of
yielded more specific evidence that parvovirus B19 is asso- HIV-associated TMA, but the literature contains little
ciated with collapsing glomerulopathy [70]. Other studies work that extends these studies to the kinds of specific
have shown that parvovirus B19 DNA is commonly abnormalities you refer to. One problem is the lack of
found in renal tissue from patients with a variety of renal a defined and sufficiently large group of patients who
diseases, and was not limited to focal and segmental can be studied for such alterations. It would be nice to
glomerulosclerosis and collapsing glomerulopathy [71]. have a registry of these individuals so that sufficient
numbers of patients can be studied to make meaningfulSo while some evidence suggests that parvovirus could
conclusions about risk factors and pathogenetic mecha-play a role in this disorder, we have insufficient evidence
nisms. Several laboratories, including Remuzzi’s group,to establish causality or specificity of this virus for this
have looked at the presence of specific metalloproteasedisorder. Other viral infections probably are good candi-
activity against von Willebrand factor multimers that isdates for causing this lesion. It is possible that some
linked to TTP and allows differentiation from otherthrombotic microangiopathies are also a result of an
forms of thrombotic microangiopathy [48, 49]. Such stud-infection by an as-yet-unrecognized virus, perhaps one
ies would be of value, but to the best of my knowledge,in which the pathogenicity is strengthened by concurrent
these studies have not been done in the HIV-infected
HIV infection. However, unlike the case of collapsing
patient population. Kelton’s group has suggested that
glomerulopathy, even one such virus that could be a this metalloprotease activity might not be as specific for
candidate for direct microvascular infection leading to TTP or even thrombotic microangiopathy as first be-
this injury has yet to be identified. It is also possible lieved [72]. Most studies bearing on susceptibility have
that systemic infection with unspecified viruses can affect used in vitro model systems to test their hypotheses.
microvascular cells in ways that we are not able to recog- Another recent example is a study in which the HIV
nize. Your question introduces the multiplicity of changes envelope protein gp120 activated human arterial smooth
in the host that occur in the setting of a systemic infection muscle cells and induced the expression of tissue factor,
independent of viral infection of specific renal tissues. an important procoagulant molecule [73]. It has been
There is a host-cytokine response to infection with alter- difficult to test the importance of this type of result in
patients or in a relevant in vitro model.ations in circulating cytokines, as well as locally produced
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Dr. John T. Harrington (Dean, Tufts University are clearly syndromes of renal insufficiency that are associ-
ated with characteristic microvascular changes and thrombiSchool of Medicine): What techniques do you use to
protect pathology lab workers who are handling HIV in small blood vessels, and with characteristic glomerular
changes of mesangiolysis and capillary loop expansionspecimens?
Dr. Alpers: I share with our hospital epidemiologist with basement membrane splitting and intracapillary
thrombosis, that occur without much evidence of anemiaand hospital infection control staff the presumption that
all patients could be HIV infected. We didn’t know in or any other systemic finding. As you indicate, such cases
are clearly those of a renal-limited form of TMA, and theadvance about the HIV status of today’s patient; the
history was obtained at the time we received the biopsy only way I know to establish the diagnosis of a primarily
renal-limited form of TMA is by renal biopsy. What Ispecimen. We try to treat all patients and their tissues the
same (that is, we use universal precautions), regardless of don’t know is whether there is a changing incidence of
TMA within renal biospy practice in general, or howhow much we know about their status with respect to
HIV or other infectious agents. However, in reality, if we changes in community standards about the thresholds
for performing renal biopsy have affected the perceivedknow that somebody has HIV, we do a few other things
to protect ourselves. In pathology, we have a set of instru- incidence of TMA. My own sense is that the frequency
of TMA in renal biopsy practice is increased as a conse-ments and sectioning equipment dedicated to potentially
infectious tissues. These are disinfected with bleach, and quence of transplantation-related injuries (for example,
calcineurin inhibitor toxicity) but that no major changesautoclaved and decontaminated after each use. Only ex-
perienced personnel are allowed to cut histologic sec- in frequency exist in the non-transplant renal patient pop-
ulation. For example, sporadic increases can result fromtions. All personnel use double gloves when handling
tissue specimens, and metal gloves are available for those infections or new drug toxicities, and we might see a dimin-
ishing incidence of radiation nephropathy and severewho prefer them. We minimize the use of unfixed tissues,
and in turn fix tissues promptly. Complete facial protec- hypertension, with other entities more or less being the
same. This is admittedly a crude assessment, and it doestion—masks, eye protection, and at times respirators—
are a requirement when handling tissues. not take into account caveats like variability in clinician
thresholds for biopsy.Dr. Harrington: My second question regards the di-
agnosis of HUS either after HIV infection or after trans- Dr. Andrew S. Levey (Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Haveplantation. It seems to me that in the past, HUS or
TTP was relatively easy to diagnose clinically. Cutaneous you searched for these markers of tunelosis, for instance,
in your rat antibody-induced mesangiolysis or anti-endo-findings, renal abnormalities, and microangiopathy were
present, and the platelet count was very low. Now, we’re thelial cell antibody model of TMA, or in the transgenic
mice that Dr. Klotman used to investigate HIV infectionseeing patients with few hematologic findings, yet the
renal pathology in many patients in whom the disease and its renal affects? Also, you raised the interesting
question of whether the injury is related to HIV infectionwas not suspected turns out to be thrombotic microangi-
opathy. Did we just miss these patients in the past or per se.
Dr. Alpers: We have not evaluated our markers inhas something changed?
Dr. Alpers: This is an important question, and one the transgenic mouse models that you refer to. It might
be an interesting thing to do. To the best of my knowl-that comes up often in clinical practice when a diagnosis
of TMA is made by renal biopsy. It is my experience, edge, these mice develop features of glomerulosclerosis
and tubular injury, but they do not develop features ofand I think that of many others, that renal biopsies are
rarely obtained from patients with renal abnormalities a TMA. Some studies have looked at apoptosis in these
mice, but broad areas of tissue injury, as exemplified inin whom pathognomonic findings of TMA such as mi-
croangiopathic hemolytic anemia and thrombocytopenia our HIV-2 infected macaques, have not been reported
in these models. Apoptosis has been studied by TUNELare present. However, TMA is a fairly common renal
biopsy diagnosis, and the patients who have this diagno- staining techniques and by ultrastructural morphology
in both the anti-Thy-1 and anti-endothelial cell antibodysis established by biopsy usually do not have overt or
prominent hematologic abnormalities. These are patients injury models. Apoptotic injury can be identified in these
models, principally in mesangial regions during the re-in whom the diagnosis cannot be established from look-
ing at a peripheral blood smear and identifying frag- parative process and also in some portions of the tubulo-
interstitial parenchyma, but no broad tissue areas of in-mented red blood cells. In my experience, it is not un-
usual for hematologists who are brought into consultation jury correspond to what we have seen in the macaque
infection model. Apoptosis, when present, mostly ap-at that point in a patient’s evaluation to resist any diagno-
sis of HUS or TTP, absent these hematologic abnormali- pears to involve individual or very small groups of cells
within specific tissue compartments. We have a study un-ties. For individuals of this persuasion, the kind of patient
you are describing conceptually does not exist. Yet, there derway to see whether this phenomenon can be broadly
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extended to TMA as it occurs in human kidneys, includ- Dr. Alpers: I would hesitate to make definitive state-
ments about that. Most of what we know about theing studies both of individuals with HIV-2 infection as
well as those whose TMA is due to various causes of function of the chemokines and their receptors is their
ability to recruit specific classes of leukocytes to sites ofthis injury (Table 1). Our initial studies have not identified
a process comparable to that in the monkey model. We injury and hence modulate specific immune and inflam-
matory responses. They can be important in organ devel-have had the opportunity to study only two cases of
human HIV-2-associated TMA in this manner. opment; as an example, CSCR4 and its chemokine ligand
SDF-1 have been shown to be important in the develop-Dr. Madias: Have endothelial function and the nitric
oxide system of HIV-infected patients or animals been ment of the immune, circulatory, and central nervous
systems [79]. How certain chemokine receptors came toexamined?
Dr. Alpers: I know of no tests of endothelial function their roles as co-receptors of viral entry into cells is
something of a mystery. Activation of chemokine recep-that have been directly linked to HIV infection, nor am
I aware of such studies in relevant animal models. It tors does lead to intracellular signaling events, and I am
aware of studies that demonstrate that engagement ofis known that treatment of HIV-infected patients with
protease inhibitors can cause hyperlipidemia, lipoprotein these receptors by the HIV envelope protein, for exam-
ple, leads to intracellular signaling events [73], but I don’tabnormalities, and hyperglycemia. Recognizing that these
are risk factors for cardiovascular disease, some investi- know that the significance of such interactions has been
well worked out. I also don’t know how specific suchgators have tested endothelial function in large arteries
(brachial artery responses measurable by ultrasound) engagement of relevant chemokine receptors with down-
stream signaling is for different viruses, virus subtypes,and demonstrated general endothelial functional impair-
ments in HIV-infected patients taking this class of drugs or viral peptides. I have to plead ignorance for much of
your question.[74]. One other recent study showed diminished circulat-
ing levels of leukocyte adhesion molecules (soluble Dr. Harrington: To the best of your knowledge, is
nitric oxide, or its lack, involved in the TMA destructiveVCAM-1) and von Willebrand factor, both released by
damaged endothelium, in HIV-infected patients taking process?
Dr. Alpers: I don’t think anybody really knows forvarious regimens of antiretroviral therapy [75]. It is not
clear whether this was an effect of the actual therapy or certain. Rick Johnson’s group at Baylor has taken the
glomerular anti-endothelial cell antibody model andits efficacy in reducing viral load. It is also not clear what
role the HIV infection played in causing the release of looked at a number of factors by which the injury might
be ameliorated or exacerbated. They found that adminis-endothelial cell products into the circulation in the first
place. tration of L-NAME, an inhibitor of nitric oxide synthesis,
exacerbated endothelial injury and resulted in more apo-There are conflicting reports on the roles of the NO
system in TMA in general, and I don’t know of studies ptosis and thrombosis [78]. Their data offer some evi-
dence of nitric oxide involvement in TMA injury. As anapplicable specifically to HIV-associated TMA. Remuzzi’s
group reported increased NO activity in patients with aside, this group also has provided evidence that vascular
endothelial growth factor (VEGF) can be protective ofrecurrent TMA [76]. Studies in experimental TMA in ro-
dents suggest that endothelial nitric oxide synthase (eNOS) renal injury in this rat model [80].
Dr. Harrington: You mentioned that the TMA injuryin particular is protective in TMA renal injury [77, 78].
Dr. V. Balakrishnan (Division of Nephrology, New in the Thy-1 model was reversible, at least in some in-
stances. Has reversible disease been shown in humans?England Medical Center): My understanding is that endo-
thelial cells are relatively slow-growing, long-lived cells If so, to what extent?
Dr. Alpers: The basic anti-Thy-1 antibody model, ifthat bear Fas ligand. You alluded to some data that HIV
turns on Fas expression in endothelial cells. Did you look you don’t modify it or administer multiple doses of anti-
Thy-1 antibody, is typically reversible just like the anti-for Fas expression in the HIV-infected macaque model?
Dr. Alpers: We did not. We tried to adapt some re- endothelial cell antibody in the rat. The human disease
is potentially reversible as well. Typical syndromes ofagents that detect human Fas using immunohistochemis-
try for similar use in monkeys, but we found that they did infection-related hemolytic-uremic syndrome in children
have a self-limited course with a return to normal renalnot work well. I can’t say that we’ve worked extensively
at it. In view of the data in human TMA that I discussed function. I have direct experience from my renal biopsy
practice that thrombotic microangiopathies resulting fromearlier, it seems that a renewed effort to test the impor-
tance of Fas pathways in TMA would be worthwhile. toxicity of drugs, such as cyclosporine, can be reversed
with removal of the offending drug from the patient’sDr. Madias: Regarding the co-receptor molecules you
referred to, are those only important for HIV entry into immunosuppression regimen. We believe that the anti-
Thy-1 and anti-endothelial cell antibody experimentalcells, or do they also influence cellular response to infec-
tion? systems are particularly good models for these kinds
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deficiency virus infection: Recovery before antiretroviral therapyof self-limited thrombotic microangiopathic injuries in
without specific treatment against TMA. Clin Nephrol 55:404–407,
humans, which begin with relatively defined onset and 2001
initiating stimuli. That is not to say that all such cases 15. Laszik Z, Silva FG: Hemolytic-uremic syndrome, thrombotic
thrombocytopenic purpura, and systemic sclerosis (systemic sclero-in humans are reversible. Unfortunately for the patient
derma), in Heptinstall’s Pathology of the Kidney (5th ed), Philadel-we discussed today, he presented with advanced renal phia, Lippincott-Raven, 1998, pp 1003–1057
disease. The thrombotic microangiopathy was an insu- 16. Obrig TG, Louise CB, Lingwood CA, et al: Endothelial heteroge-
neity in Shiga toxin receptors and responses. J Biol Chem 268:15484–perable additional injury that pushed the patient to end-
15488, 1993stage renal disease. He never recovered from this episode 17. Gadallah MF, el-Shahawy MA, Campese VM, et al: Disparate
of TMA and went on to requiring maintenance dialysis. prognosis of thrombotic microangiopathy in HIV-infected patients
with and without AIDS. Am J Nephrol 16:446–450, 1996
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